Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2018

Jul 31, 2018

SELL
$8.55 - $13.76 $86,722 - $139,567
-10,143 Closed
0 $0
Q1 2018

May 09, 2018

BUY
$8.99 - $14.95 $91,185 - $151,637
10,143 New
10,143 $93,000

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $464M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Rockefeller Capital Management L.P. Portfolio

Follow Rockefeller Capital Management L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

News

Stay updated on Rockefeller Capital Management L.P. with notifications on news.